Novo Nordisk Partners with Replicate Bioscience in $550M Deal to Advance srRNA Therapeutics for Cardiometabolic Diseases

On August 28, Novo Nordisk and Replicate Bioscience entered into a multi-year research collaboration agreement. Based on Replicate's novel srRNA platform, the two parties will collaborate on certain targets in cardiometabolic diseases to jointly develop new therapeutic candidates for the treatment of obesity, type 2 diabetes, and other cardiometabolic conditions.

According to the terms of the agreement, Novo Nordisk will obtain clearGlobal Exclusive License, using Replicate's srRNA platform to develop and commercialize leading projects.Replicate Bioscience will receive research funding and is eligible for up to $550 million (approximately 3.923 billion RMB) in funding from Novo Nordisk.Including upfront cash payments and potential milestone payments, with eligibility for future tiered royalties on product sales.

Replicate Bioscience is a clinical-stage company pioneering the application of next-generation self-replicating RNA (srRNA) technology in infectious diseases, immunology, and other therapeutic areas. Previously, data from its rabies srRNA vaccine RBI-4000 showed that it could induce protective immunity in mice at a much lower dose compared to mRNA vaccines; in human trials, it still elicited a strong immune response at doses as low as 0.1 micrograms, with good safety.

Low dose, long-acting effects, and broadening the therapeutic window will be the key to breaking through for srRNA.

In most biological systems, the half-life of exogenous mRNA is limited, especially in rapidly dividing cells. In contrast, viral RNA can extend its lifespan by actively replicating within the host. Therefore, they can serve as a framework for designing synthetic srRNA, using their own RNA sequences as templates for self-replication.

Therefore, the advantage of srRNA in pharmaceutical applications lies inAchieve the same protein expression level as traditional mRNA with a much lower dose, enhance bioactivity, prolong in vivo expression duration, induce a stronger and more durable cellular immune activation response, and improve tolerance.

These application features make it inTumor Immunotherapy, Clearing Chronic Latent Viruses...and other aspects have inherent advantages, being able to address the shortcomings of existing mRNA antibodies such as rapid titer decline and insufficient duration of immune protection. However, due to relatively high technical barriers and significant challenges in process development, research and pharmaceutical practice in this area remain "niche."

As a portfolio company incubated by Apple Tree Partners,Replicate Bioscience, with its team of srRNA experts, customizable synthetic srRNA vector library, and end-to-end development capabilities, is gradually expanding the scope of RNA therapeutics.Infectious Diseases, Immuno-Oncology, Autoimmune DiseasesAnd other fields.

Specifically, Replicate's off-the-shelf srRNA consists of two components: a viral-derived genetic code that drives controlled and self-limiting amplification, and RNA encoding therapeutic proteins. The company’s library of viral vectors has been carefully selected to drive robust and sustained protein expression, with performance several orders of magnitude higher than linear mRNA, offering greater durability and tunability in vivo.

In July 2022, Replicate Bioscience and Precision NanoSystems (PNI) announced a licensing agreement, under which PNI will provide lipid nanoparticle solutions for the scale-up and production of up to 15 Replicate srRNA therapies.

In addition, Replicate has built a proprietary end-to-end integrated drug development platform, which not only optimizes gene insertion into self-replicating vectors but also matches suitable ones from the library based on characteristics such as indications.Next-generation srRNA vectorReplicate Bioscience stated that this proprietary technology will deliver a 1000-fold expression gain for linear mRNA and a 100-fold expression gain for standard srRNA.

From its own pipeline, Replicate Bioscience focuses onInfectious Diseases(Vaccine), Immuno-Oncology, Autoimmune DiseasesThree major sectors.On the treatment front, Precision Immuno-Oncology (PIO) is Replicate's new approach to predictable resistance mutations, which occur when cancer cells evolve to evade treatment.

The fastest clinically advancing RBI-1000 targetsAcquired Resistance Mutations (ARM) in Estrogen Receptor-Positive (ER+) First-Line Metastatic Breast CancerAt the 2023 American Association for Cancer Research (AACR) Annual Meeting Replicate sharing session, in mouse models expressing targeted acquired resistance mutations, RBI-1000 successfully induced CD4+ and CD8+ T cells, leading to significant tumor growth inhibition and improved survival rates at a dose 100 times lower than linear mRNA approaches used in other tumor models.

In addition, in the public information, Replicate has also disclosed RBI-3000 (Targeted Acquired Resistance to Current Standard Tyrosine Kinase Inhibitor Treatment in Metastatic EGFRm+ Non-Small Cell Lung Cancer) and RBI-2000.

RBI-2000 isThe first srRNA encoding multiple biologic therapeutic proteins on a single vector backbone, at lower doses, exhibits better bioactivity and a more persistent tumor immune response compared to linear mRNA approaches. Using a novel srRNA vector, RBI-2000 encodes two different proteins on a single RNA strand: one is a multimeric protein that promotes the generation of new immune cells, and the other is a monomeric protein that prevents sterile inflammation, abnormal angiogenesis, and tumor invasion. Preclinical studies have shown that 70 days after treatment, mice with complete responses were rechallenged with tumor cells and successfully rejected the attack, indicating strong immunological memory at this time.

However, despite the deep layout in the treatment field, the novelty and cutting-edge nature of srRNA still led Replicate Bioscience to choose preventive vaccines as the first step for human trials.The first to enter human trials is the srRNA vaccine RBI-4000 for the prevention of rabies, which stimulates a virus-neutralizing immune response to rabies.

In the first Phase I clinical data disclosed in February 2025, srRNA demonstrated excellent efficacy—no serious adverse events occurred in any of the dose groups.No dose-limiting toxicity was observed at the 10 microgram dose level.Well tolerated. In terms of immunogenicity, according to the initial immunization -Strengthening Immunization Program,Most participants developed new protective immunity when administered doses of 0.1 micrograms, 1 microgram, or 10 micrograms.Even with a single dose,1 microgram and 10 microgram doses also enabled the majority of participants to exceed the WHO protective benchmark for immunity levels.

Notably, this human trial demonstrates thatOptimized srRNA Vaccines Outperform First-Generation srRNA Vaccines in Both Bioactivity and Safety, it also has potential application value in the fields of multi-gene or multivalent vaccines, cancer vaccines, and protein replacement therapies in the future. This means that,srRNA Product Moves One Step Closer to Therapeutic Applications.

After the vaccine achieves preliminary concept validation, developing therapeutic products becomes a key transition for many small nucleic acid and mRNA companies. This might be precisely the critical point where Novo Nordisk decided to start funding research and development.

In just three years, Novo Nordisk has completed the "deification" of the weight-loss drug market, from shortages, price hikes, and capacity expansion, to tirzepatide competition, indication expansion, and generic drug pursuit, inevitably leading to the inevitable downfall from the pedestal amidst the hype.

Within the year, Novo Nordisk twiceDownward adjustmentFull-year 2025 earnings forecast,Stock price plummeted overnight by more than20%. Betting on the next generation of weight-loss drugs, or rather, deepening cardiometabolic researchField layout is its "introducing fresh blood" long-term self-rescue.

TodayYearIn January, Novo NordiskIn$190 Million Upfront Payment Plus $4.6 Billion in Milestone Payments: Multi-Year Collaboration with Valo Health Expands to up to 20 Drug Programs Targeting Obesity, Type 2 Diabetes, and Other Diseases.

In March, Novo Nordisk invested $2 billion to collaborate with Federal Pharmaceutical on the development of a GLP-1/GIP/GCG triple receptor agonist, securing exclusive rights for development, production, and commercialization outside mainland China, Hong Kong SAR, Macao SAR, and Taiwan region, with a potential total amount reaching up to $2 billion.

June,Novo Nordisk Spends Again, Investing$812 million collaboration with Deep Apple Therapeutics to leverage its proprietary technology for developing non-enteropancreatic oral weight loss therapies.

Tracing back further, Novo Nordisk's peak in the cardiometabolic field was already reached in 2023 —

In August, a $1.075 billion acquisition of Canadian company Inversago Pharma secured INV-202, which blocks the CB1R receptor protein in peripheral tissues; a $471 million acquisition of Danish company Embark Biotech obtained peptide and small molecule pipelines targeting neurokinin receptor 2 (NK2R), as well as energy metabolism drugs.

When semaglutide begins to show potential in the cardiovascular field, rapidly acquire and expand the pipeline to form synergies ——Launched the accelerator platform LAB eN² in collaboration with German company Evotec, targeting the cardiometabolic disease field; entered into a $2.7 billion collaboration with AI drug development company Valo Health, acquiring three preclinical cardiometabolic disease programs; partnered with Broad Institute to leverage large-scale cell screening for discovering new targets for type 2 diabetes and cardiometabolic diseases.

New mechanism, emerging targets, long-acting properties,Biotechs at the forefront of innovation have become the focal point of Novo Nordisk's collaborations. For multinational corporations (MNCs), business development (BD) partnerships are not always a "high-stakes gamble"; they may simply be an "angel investment."

Replicate Bioscience, Inc. is an excellent candidate that meets the criteria, with both superior safety and human data, as well as unique advantages of "low dosage" and "long-acting" in srRNA.